Biogen (BIIB) Tops Q4 EPS by 8c; FY17 Rev Guidance Falls Below the Street
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Biogen Reports 2016 Revenues of $11.4 Billion
January 26, 2017 6:30 AM EST2016 GAAP diluted EPS rise 10%; Non-GAAP diluted EPS rise 19%
Board of Directors Appoints Michel Vounatsos as Chief Executive Officer
SPINRAZATM Approved and Launched in the US for Spinal Muscular Atrophy
Biogen and Forward Pharma Agree to Enter into Settlement and License Agreement
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Biogen Inc. (NASDAQ: BIIB) today reported full year and fourth quarter 2016 financial results, including:
Full year total revenues of $11.4 billion, a 6% increase versus the prior year. On a constant currency basis1, total... More